VOLUME 59   1998   NUMBER 5

Brainstorms

215 Recognition Molecules Are Trailblazers for Axon Pathways. Stephen M. Stahl
[PDF]

Original Articles

217 Treatment of Major Depression in HIV-Seropositive Men. Sidney Zisook, Joanna Peterkin, Kathleen J. Goggin, Paul Sledge, J. Hampton Atkinson, Igor Grant, and the HIV Neurobehavioral Research Center Group
[Abstract] [PDF]

225 Tobacco Smoking and Bipolar Disorder. Ana Gonzalez-Pinto, Miguel Gutierrez, Jesus Ezcurra, Felipe Aizpuru, Fernando Mosquera, Purificacion Lopez, and Jose de Leon
[Abstract] [PDF]

229 Dose-Response Efficacy of Paroxetine in Preventing Depressive Recurrences: A Randomized, Double-Blind Study. Linda Franchini, Mariangela Gasperini, Jorge Perez, Enrico Smeraldi, and Raffaella Zanardi
[Abstract] [PDF]

233 Safety of Mirtazapine in Overdose. James D. Bremner, Peggy Wingard, and Thomas A. Walshe
[Abstract] [PDF]

236 Once- Versus Twice-Daily Venlafaxine Therapy in Major Depression: A Randomized, Double-Blind Study. Jay D. Amsterdam, Mary B. Hooper, and Jess Amchin
[Abstract] [PDF]

241 A Post Hoc Comparison of Paroxetine and Nortriptyline for Symptoms of Traumatic Grief. Marianne Zygmont, Holly G. Prigerson, Patricia R. Houck, Mark D. Miller, M. Katherine Shear, Selby Jacobs, and Charles F. Reynolds III
[Abstract] [PDF]

246 A Double-Blind, Placebo-Controlled Trial of Nefazodone in the Treatment of Patients Hospitalized for Major Depression. John Feighner, Steven D. Targum, Mary Ellen Bennett, Douglas L. Roberts, Terry T. Kensler, M. Frances D'Amico, and Sterling A. Hardy
[Abstract] [PDF]

Academic Highlights

259 Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Other Psychiatric Disorders. Part I: Unique Patient Populations.
[PDF]

CME Activity 266

267 Hoarding: A Symptom, Not a Syndrome. Claire L. Damecour and Maryse Charron
[Abstract] [PDF]

Letters To The Editor

254 Is Risk of Neuroleptic Malignant Syndrome Increased in the Postpartum Period? Panickacheril J. Alexander, Ranji M. Thomas, and Arunava Das
[PDF]

255 FINISH: Remembering the Discontinuation Syndrome. Mark J. Berber
[PDF]

255 Risperidone May Worsen Fluoxetine-Treated OCD. Chittaranjan Andrade
[PDF]

Reply by Sanjaya Saxena and Alexander Bystritsky [PDF]

256 Nefazodone and the Treatment of Panic. MAJ Timothy R. Berigan, CPT Antonio Casas, and Jeff Harazin
[PDF]

257 Gastroesophageal Reflux as a Possible Result of Clozapine Treatment. Robert W. Baker and K. N. Roy Chengappa
[PDF]

Book Review 258

Information for authors

see January 1998, pages 33_34